Tumor Immunotherapy for the Treatment of Cutaneous Melanoma
Publication Date: October 18, 2023
Key Points
Key Points
- Cutaneous melanoma continues to be a serious public health threat with a slow but steady increase in annual incidence over the past four decades.
- In 2017, there were an estimated 87,110 new cases and 9,730 deaths due to melanoma in the United States.
- Since 2011, the treatment landscape for patients with melanoma has changed considerably with regulatory approval of 11 new drugs and/or combination regimens.
- Immunotherapy agents in particular have been associated with durable long-term survival in responding patients and have emerged as first-line treatment in most melanoma populations.
- The Society for Immunotherapy of Cancer (SITC), a non-profit professional organization dedicated to improving cancer patient outcomes through the use of immunotherapy, established an expert panel – the Melanoma Task Force – to provide consensus recommendations for clinical decision making for patients with melanoma.
- These recommendations are not intended to supplant sound clinical judgment but to provide clinicians who care for melanoma patients the most current thinking on how experts integrate immunotherapy into the treatment armamentarium for patients with advanced cutaneous melanoma.
Immunotherapy for Melanoma
...mmunotherapy for Melano...
Table 1. Clinical Issues in Tumor Immunotherapy for Cutaneous Melanoma
...cal Issues in Tumor Immunotherapy for Cutaneous...
Figure 1. Stage II Melanoma Immunotherapy Treatment Algorithm
...1. Stage II Melanoma Immunotherapy Treatm...
Figure 2. Stage III N1a (7th)/Stage IIIA (8th) Melanoma Immunotherapy Treatment Algorithm
...2. Stage III N1a (7th)/Stage IIIA (8th...
Figure 3. Stage III N1b-3 (AJCC 7th)/Stage IIIB-D (AJCC 8th)
...e III N1b-3 (AJCC 7th)/Stage IIIB-D (AJCC 8th)...
Figure 4. Stage IV Melanoma Immunotherapy Treatment Algorithm
Figure 4. Stage IV Melanoma Immunother...
Table 2. Immunotherapy Agents for Melanoma
...unotherapy Agents for MelanomaHaving tr...